Sandu Pharmaceuticals Peer Comparison

Sandu Pharmaceuticals Ltd. shows potential in the context of profitability and growth compared to its peers, although its financial metrics indicate it is underperforming in valuation and efficiency. Companies like Cipla and Dr. Reddy's demonstrate stronger profitability and valuation attractiveness, while Sandu's low debt level is a positive aspect in a sector where many companies exhibit higher leverage.

• • Sandu Pharmaceuticals has a low debt-equity ratio of 0, indicating no reliance on debt financing.
• • The company shows a low ROE of 3.66%, suggesting less efficiency in generating profits compared to peers.
• • With a PE ratio of 29.42, Sandu is relatively expensive compared to peers like Dr. Reddy's, which has a PE of 15.50.

• • Cipla Ltd.: Strong revenue growth of 13.28% YoY and the lowest PE ratio among peers, indicating good valuation.
• • Dr. Reddy's Laboratories Ltd.: High ROE of 21.76% and a very low PE of 15.50, making it an attractive investment.
• • Mankind Pharma Ltd.: Exceptional revenue growth of 18.12% YoY and solid profitability metrics.